



REPUBLIC OF THE PHILIPPINES
OFFICE OF THE PRESIDENT

DANGEROUS DRUGS BOARD

**BOARD REGULATION NO. 2
SERIES OF 2024**

SUBJECT: EXTENSION OF THE PROVISIONAL REMOVAL OF LIANHUA QINGWEN FROM THE LIST OF DANGEROUS DRUGS FOR ANOTHER PERIOD OF ONE (1) YEAR

WHEREAS, the Dangerous Drugs Board (the "Board") under Section 81 of Republic Act No. 9165 (RA 9165) or the Comprehensive Dangerous Drugs Act of 2002 is mandated to "formulate guidelines, in coordination with other government agencies, relative to transactions involving dangerous drugs and controlled precursors and essential chemicals, which may include the importation, distribution, sale, prescription, and dispensing thereof";

WHEREAS, pursuant to the above mandate, the Board, in Resolution No. 1, Series of 2020, interposed no objection to the product registration of Lianhua Qingwen capsules with the Food and Drug Administration (FDA) of the Department of Health, provided that should the FDA issue a Certificate of Product Registration, the importer thereof shall secure the proper license from the Philippine Drug Enforcement Agency and comply with all the regulatory requirements set forth in Board Regulation No. 1, Series of 2014;

WHEREAS, on 4 February 2021, the Board promulgated Regulation No. 1, Series of 2021 approving the Provisional Removal of *Lianhua Qingwen* from the List of Dangerous Drugs for a Period of One (1) Year pursuant to Section 93 of RA 9165 which further provides that prior to the expiration of the one-year period, the Committee on Reclassification shall evaluate and recommend to the Board whether to shorten or extend the said period given the prevailing circumstances at such time;

WHEREAS, on 24 January 2022, the Board adopted Regulation No. 1, Series of 2022 extending the grant of the provisional removal of *Lianhua Qingwen* from the list of Dangerous Drugs for another one (1) year;

WHEREAS, on 09 February 2023, the Board once again extended the grant of the provisional removal of *Lianhua Qingwen* from the list of Dangerous Drugs for another one (1) year through Regulation No. 1, Series of 2023;

WHEREAS, on 19 January 2024, the Philippine Archipelago International Trading Corporation submitted a formal letter to the Board, requesting for an extension of the provisional removal of Lianhua Qingwen from the List of Dangerous Drugs based on the recognized efficacy of Lianhua Qingwen in managing symptoms associated with the surge of COVID-19;

WHEREAS, Lianhua Qingwen capsules is duly registered with the FDA under registration number THPR-50, valid until 7 August 2025, categorized under the Pharmacologic classification of Traditionally-Used Herbal Products with the designated use to assist in the alleviation of heat-toxin invasion symptoms affecting the lungs, including but not limited to fever, aversion to cold, muscle soreness, and nasal congestion;

WHEREAS, the Technical Working Group on Reclassification, Addition, or Removal (TWG-RAR) of Drugs/Substances from the List of Dangerous Drugs/Controlled Precursors and Essential Chemicals convened on 28 February 2024 to discuss the request;

WHEREAS, members of the TWG-RAR noted that since the introduction of *Lianhua Qingwen* capsules in the Philippine market, there have been (a) no documented cases of adverse reactions, instances of overdose, or drug abuse associated with *Lianhua Qingwen*; and (b) no reported seizures nor incidents of diversion related to the ephedra and ephedrine content in the said product;

WHEREAS, the TWG-RAR recommended to grant the request for the extension of the provisional removal of *Lianhua Qingwen* from the list of dangerous drugs that was presented to the Board for its approval;

WHEREFORE, be it **RESOLVED**, as it is hereby **RESOLVED**, to further extend the provisional removal of Lianhua Qingwen from the List of Dangerous Drugs for another period of one (1) year;

APPROVED and **ADOPTED** this 8th day of March, in the year of Our Lord, 2024, in Quezon City, Philippines.


Secretary **CATALINO S. CUY, CEO VI**
Chairman

Attested by:


Undersecretary **EARL P. SAAVEDRA, CESO I**
Board Secretary / Executive Director